Spots Global Cancer Trial Database for Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma

Official Title: Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma

Study ID: NCT00094107

Conditions

Melanoma

Skin Neoplasms

Interventions

Axitinib [AG-013736]

Study Description

Brief Summary: This is a Phase 2 study being conducted at multiple centers in the United States and France. Patients having melanoma that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that has been treated with no more than 1 prior treatment for metastatic disease (prior adjuvant treatment for localized disease does not count as prior treatment for metastatic disease). The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic melanoma as shown by the number of patients in the study who experience significant and durable tumor shrinkage.

Detailed Description: